Sensitivity analysis using 14 day control periods 11, 12 and 13 months before the index date yielded results consistent with the main results (Table 5). The number of patients for each NPAE is described in Table S5.
Sensitivity analysis of risk of NPAEs associated with the use of oseltamivir over the preceding 14 days using control periods (11, 12 and 13 months before the index date)
| First control period . | No. (%) . | Crude OR (95% CI) . | P . | aORa (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| exposed in hazard period (n = 5322) . | exposed in control period (n = 15 966) . | |||||
| 11 months before the index date | 139 (2.6) | 215 (1.3) | 2.03 (1.63–2.54) | <0.0001 | 1.59 (1.27–2.00) | <0.0001 |
| 12 months before the index date | 139 (2.6) | 278 (1.7) | 1.57 (1.27–1.95) | <0.0001 | 1.33 (1.07–1.66) | 0.0118 |
| 13 months before the index date | 139 (2.6) | 196 (1.2) | 2.24 (1.79–2.81) | <0.0001 | 1.73 (1.37–2.18) | <0.0001 |
| First control period . | No. (%) . | Crude OR (95% CI) . | P . | aORa (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| exposed in hazard period (n = 5322) . | exposed in control period (n = 15 966) . | |||||
| 11 months before the index date | 139 (2.6) | 215 (1.3) | 2.03 (1.63–2.54) | <0.0001 | 1.59 (1.27–2.00) | <0.0001 |
| 12 months before the index date | 139 (2.6) | 278 (1.7) | 1.57 (1.27–1.95) | <0.0001 | 1.33 (1.07–1.66) | 0.0118 |
| 13 months before the index date | 139 (2.6) | 196 (1.2) | 2.24 (1.79–2.81) | <0.0001 | 1.73 (1.37–2.18) | <0.0001 |
Conditional logistic regression adjusted for important potential time-varying confounding variables including diagnosis of influenza, prescription of NSAIDs, opioid drugs, benzodiazepines, antidepressants, zolpidem, histamine-2 receptor antagonists and corticosteroids.
Sensitivity analysis of risk of NPAEs associated with the use of oseltamivir over the preceding 14 days using control periods (11, 12 and 13 months before the index date)
| First control period . | No. (%) . | Crude OR (95% CI) . | P . | aORa (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| exposed in hazard period (n = 5322) . | exposed in control period (n = 15 966) . | |||||
| 11 months before the index date | 139 (2.6) | 215 (1.3) | 2.03 (1.63–2.54) | <0.0001 | 1.59 (1.27–2.00) | <0.0001 |
| 12 months before the index date | 139 (2.6) | 278 (1.7) | 1.57 (1.27–1.95) | <0.0001 | 1.33 (1.07–1.66) | 0.0118 |
| 13 months before the index date | 139 (2.6) | 196 (1.2) | 2.24 (1.79–2.81) | <0.0001 | 1.73 (1.37–2.18) | <0.0001 |
| First control period . | No. (%) . | Crude OR (95% CI) . | P . | aORa (95% CI) . | P . | |
|---|---|---|---|---|---|---|
| exposed in hazard period (n = 5322) . | exposed in control period (n = 15 966) . | |||||
| 11 months before the index date | 139 (2.6) | 215 (1.3) | 2.03 (1.63–2.54) | <0.0001 | 1.59 (1.27–2.00) | <0.0001 |
| 12 months before the index date | 139 (2.6) | 278 (1.7) | 1.57 (1.27–1.95) | <0.0001 | 1.33 (1.07–1.66) | 0.0118 |
| 13 months before the index date | 139 (2.6) | 196 (1.2) | 2.24 (1.79–2.81) | <0.0001 | 1.73 (1.37–2.18) | <0.0001 |
Conditional logistic regression adjusted for important potential time-varying confounding variables including diagnosis of influenza, prescription of NSAIDs, opioid drugs, benzodiazepines, antidepressants, zolpidem, histamine-2 receptor antagonists and corticosteroids.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
